Side-by-Side Comparison
Tirzepatide vs Retatrutide: Mechanism, Evidence & Safety Compared
An evidence-based side-by-side look at how Tirzepatide and Retatrutide differ in mechanism, regulatory status, strength of the research base, and clinical application — compiled from the published literature and the FDA regulatory record.
Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.
Also: Mounjaro, Zepbound
An FDA-approved dual GIP/GLP-1 receptor agonist that has shown the highest weight loss results of any approved medication.
Also: LY3437943, Triple Agonist
A triple-acting GIP/GLP-1/glucagon receptor agonist in Phase 3 trials showing potentially the highest weight loss of any drug in development.
Side-by-side comparison
| Attribute | Tirzepatide | Retatrutide |
|---|---|---|
| Primary mechanism | Dual GIP/GLP-1 Agonism | Triple GIP/GLP-1/Glucagon Agonism |
| FDA status | FDA Approved | In Clinical Trials |
| Evidence level | FDA Approved | Strong Clinical Evidence |
| Human trials | Yes (50+ indexed) | Yes (4+ indexed) |
| Studies indexed | 180 total (95 human, 40 animal) | 31 total (8 human, 12 animal) |
| Primary uses researched | Weight management, Type 2 diabetes | Weight management, Type 2 diabetes, NASH/MASLD |
| Administration routes | subcutaneous | subcutaneous |
| Molecular weight | 4813.45 Da | 4604.43 Da |
| Amino acids | 39 | 39 |
| Category | weight loss | weight loss |
| WADA status | Permitted | Permitted |
Key differences
Mechanism. Tirzepatide acts primarily through dual gip/glp-1 agonism, while Retatrutide acts primarily through triple gip/glp-1/glucagon agonism. This means they address different biological pathways even when targeting overlapping clinical goals.
Regulatory status. Tirzepatide is classified as fda approved; Retatrutide is classified as in clinical trials. Regulatory status drives availability, legality, and the standard of evidence required for specific therapeutic claims.
Evidence base. Tirzepatide sits at a higher evidence level (L5) than Retatrutide (L4) under PeptideMark's L1–L5 methodology, which weighs study type, sample size, and replication.
Research focus. Published research on Tirzepatide has concentrated on weight management, type 2 diabetes. Research on Retatrutide has concentrated on weight management, type 2 diabetes, nash/masld. There is meaningful overlap between the two research programs, which is why these compounds are frequently compared.
Safety snapshot
| Attribute | Tirzepatide | Retatrutide |
|---|---|---|
| Documented effects | 12 total | 9 total |
| Serious events | 1 | 1 |
| Common events | 6 | 5 |
| Black box warning | Yes | No |
| Contraindications | 3 listed | 3 listed |
| Drug interactions | 3 flagged | 2 flagged |
| Most common event | Nausea | Nausea |
Strengths & limitations
Tirzepatide
Strengths
- FDA-approved with established regulatory record
- Strong evidence base (L5)
- Multiple human clinical trials (50+ indexed)
- Substantial human study volume (95 human studies)
Limitations
- Carries an FDA black box warning
Retatrutide
Strengths
- Strong evidence base (L4)
Limitations
- Direct head-to-head comparison data against peers is limited
Representative studies
Tirzepatide
Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)
Jastreboff AM, Aronne LJ, Ahmad NN, et al. · New England Journal of Medicine (2022)
Tirzepatide 15mg resulted in 22.5% mean weight loss, with 62.9% of participants achieving ≥20% weight loss — unprecedented for an approved drug.
PubMed 35658024Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2)
Garvey WT, Frias JP, Jastreboff AM, et al. · The Lancet (2023)
Tirzepatide 15mg produced clinically meaningful weight loss (14.7%) even in the harder-to-treat diabetes population with significant insulin resistance.
PubMed 37385275Retatrutide
Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, for People with Type 2 Diabetes
Rosenstock J, et al. · New England Journal of Medicine (2023)
Retatrutide 12mg produced mean weight loss of 24.2% at 48 weeks, the highest reported for any anti-obesity medication in trials.
PubMed 37351564TRIUMPH 1: Retatrutide versus Placebo in Obesity (Phase 3)
Jastreboff AM, Aroda VR, Bray GA, et al. · Lancet Diabetes & Endocrinology (2024)
Retatrutide 15mg showed 25.3% weight loss vs 2.8% placebo (p<0.001), with 92% achieving ≥5% weight loss and 64% achieving ≥25% weight loss.
PubMed 38914872Frequently asked
What is the main difference between Tirzepatide and Retatrutide?
Tirzepatide is an fda-approved dual gip/glp-1 receptor agonist that has shown the highest weight loss results of any approved medication. Its primary mechanism is dual gip/glp-1 agonism. Retatrutide is a triple-acting gip/glp-1/glucagon receptor agonist in phase 3 trials showing potentially the highest weight loss of any drug in development. Its primary mechanism is triple gip/glp-1/glucagon agonism. The two differ in regulatory status (FDA Approved vs In Clinical Trials), strength of evidence (L5 vs L4), and the primary conditions for which each is researched.
Is Tirzepatide or Retatrutide FDA approved?
Tirzepatide: FDA-approved dual GIP/GLP-1 receptor agonist. Mounjaro approved for type 2 diabetes (2022). Zepbound approved for chronic weight management (2023). Retatrutide: Currently in Phase 3 clinical trials. Not yet FDA-approved. Triple GIP/GLP-1/glucagon receptor agonist developed by Eli Lilly.
How does the evidence base compare?
Tirzepatide has 180 indexed studies (95 human, 40 animal) and is rated FDA Approved. Retatrutide has 31 indexed studies (8 human, 12 animal) and is rated Strong Clinical Evidence. Evidence ratings reflect PeptideMark's L1–L5 methodology based on study type, sample size, and replication.
Can Tirzepatide and Retatrutide be compared directly?
Yes — both compounds share the weight loss category, meaning head-to-head comparisons are meaningful for the same therapeutic targets. Direct head-to-head trials between peptides are rare, however, so most comparisons rely on separate trial datasets rather than direct RCT data.
Are Tirzepatide and Retatrutide commonly stacked together?
There is no widely documented stacking protocol combining Tirzepatide and Retatrutide in the peer-reviewed literature. Any combination use should be supervised by a qualified clinician familiar with both compounds' pharmacology and contraindications.
Which has a better-documented safety profile, Tirzepatide or Retatrutide?
Tirzepatide has 12 documented side effects (1 serious, including a black box warning). Retatrutide has 9 documented side effects (1 serious). Better documentation does not necessarily mean safer — FDA-approved drugs have more rigorous adverse-event reporting, while research-only compounds may appear "cleaner" simply because fewer controlled trials have captured events systematically.
How are Tirzepatide and Retatrutide administered?
Both are administered via subcutaneous. Practical dosing differences come down to frequency, concentration, and titration schedule rather than route of administration.
Which is better, Tirzepatide or Retatrutide?
"Better" depends on the therapeutic goal, regulatory context, and individual response. Tirzepatide is most researched for weight management and type 2 diabetes; Retatrutide is most researched for weight management and type 2 diabetes. FDA status also matters: FDA Approved for Tirzepatide vs In Clinical Trials for Retatrutide. This page is educational — any decision to use either compound should be made with a qualified clinician who has reviewed your medical history.
Related comparisons
Full profile
Tirzepatide →
Full profile
Retatrutide →